What Lerkamen 20 Treats: Main Uses and Benefits

Lerkamen 20 is commonly used in situations involving systemic imbalance, specifically chronic high blood pressure. It is relevant for easing the burden of high blood pressure, also known as essential hypertension, in adult patients. The medication is relevant in contexts involving heightened systemic burden, focusing on the chronic management of high blood pressure.

The primary therapeutic use of Lerkamen 20 includes managing mild to moderate essential hypertension. It is also used when additional symptomatic support is needed because high blood pressure is not adequately managed by another single agent, and in specific patient groups, such as older adults. This long-term support contributes to easing the overall symptom load and helps reduce the potential burden linked to high blood pressure.

“This therapeutic support assists with maintaining functional stability and supports general well-being during symptomatic phases.”

The medication is commonly used across the adult patient population and may be considered relevant for managing symptoms related to heightened physiological activity in the elderly.

---

Quick Fact: Relief for Elevated Blood Pressure The main benefit is the assistance provided to the cardiovascular system, which is relevant for easing the symptoms related to systemic imbalance over time.

Eligibility Map: Who can and cannot use Lerkamen 20 — Official Regulatory Information

The eligibility for Lerkamen 20 is strictly defined by regulatory documents, which permit use primarily for adults aged 18 years and older. Use is not recommended for children and adolescents under 18 due to insufficient data on efficacy and safety.

Contraindicated Populations

Lerkamen 20 is contraindicated (prohibited) for patients with a known hypersensitivity to Lercanidipine or any dihydropyridine, as well as those with severe organ impairment, specifically severe hepatic impairment or severe renal impairment (GFR < 30 ml/min).

Absolute contraindications also include specific cardiac conditions, such as untreated congestive cardiac failure, unstable angina pectoris, or myocardial infarction within the preceding month.

Restrictions and Conditional Use

The medicine must not be used concurrently with strong CYP3A4 inhibitors (like certain antifungals or antivirals), Cyclosporin, or grapefruit/grapefruit juice.

For pregnancy and lactation, Lerkamen 20 is not recommended and is contraindicated in women of child-bearing potential unless effective contraception is in use. Patients with mild to moderate kidney or liver impairment and those with ischemic heart disease are populations for whom special care or caution is required upon commencing treatment.

The interaction profile for Lerkamen 20 is defined by its reliance on the CYP3A4 enzyme for metabolism and its inherent vasodilating properties. Co-administration is formally contraindicated with several medicinal products due to pharmacokinetic interactions. These prohibited combinations include strong inhibitors of the CYP3A4 enzyme, such as Ketoconazole, Itraconazole, and Erythromycin, as they cause a considerable increase in Lercanidipine’s systemic exposure (up to 15-fold AUC). The immunosuppressant Ciclosporin is also contraindicated, based on documented reciprocal increases in plasma levels of both medicines.

The intake of Grapefruit or Grapefruit juice is prohibited, as it similarly inhibits metabolism and increases systemic availability. Conversely, substances that induce the CYP3A4 enzyme (e.g., Rifampicin, Phenytoin) may reduce the antihypertensive efficacy by increasing clearance.

Regarding pharmacodynamic interactions, the intake of alcohol must be avoided as it potentiates the vasodilating hypotensive effect. Caution is also noted when co-administering other antihypertensive agents due to the potential for additive hypotensive effects.

A specific timing separation rule is required to mitigate drug-food interactions: Lerkamen 20 must be taken on an empty stomach, at least 15 minutes before breakfast, since a high-fat meal significantly increases its systemic absorption. Finally, the antihypertensive effect may be enhanced in patients with mild to moderate hepatic impairment.

Lerkamen 20 contains the active compound Lercanidipine hydrochloride, which functions as a dihydropyridine calcium channel blocker. Lercanidipine selectively targets L-type voltage-gated calcium channels, primarily those located in the smooth muscle cells of systemic arterioles. The molecule interacts allosterically with a specific binding site on the alpha1 subunit of the L-type channel complex, operating as a reversible antagonist. This interaction prevents the influx of extracellular calcium ions ( Ca^2+) into the vascular smooth muscle cell cytosol.

The resulting reduction in intracellular Ca^2+ concentration limits the activation of the calcium-calmodulin complex. This, in turn, decreases the phosphorylation of the myosin light chain by myosin light chain kinase. The decreased phosphorylation reduces the ability of actin and myosin filaments to interact, leading to a diminished state of cellular contractility. The ultimate physiological consequence at the system level is peripheral arterial vasodilation and a subsequent reduction in total peripheral vascular resistance.

The administration of Lerkamen 20 (Lercanidipine hydrochloride) follows a specific protocol to standardize its use in clinical practice. The medication is an oral dosage form, available as a film-coated tablet in strengths including 10 mg and 20 mg. The central principle of use is a once-daily schedule, which should preferably be administered in the morning.

Official Administration Rules

Usage Parameter	Instruction
Dosing Regimen	The typical starting dose is 10 mg once daily. The dose may be increased to the 20 mg maintenance dose, which is generally the maximum recommended daily amount.
Food and Timing	The tablet must be taken at least 15 minutes before any meal, a critical instruction due to how food intake affects systemic availability. Intake with grapefruit or grapefruit juice is strictly restricted.
Dose Titration	Any dose increase from 10 mg to 20 mg should be gradual. The full therapeutic effect may take approximately two weeks to appear, necessitating a waiting period before adjustment.

Population-Specific Use

Use in specific populations follows established guidelines. For older adults, no general dose adjustment is required; however, special caution is advised when treatment is initiated. Lerkamen 20 is not recommended for use in children and adolescents under 18 years of age due to the absence of established safety and efficacy data. Patients with mild to moderate kidney or liver impairment should have dose increases approached with caution. The tablet may be divided into equal halves to aid administration, if necessary.

Recent Clinical Evidence

Core Research on Lercanidipine and Hypertension

Research evidence explores whether Lercanidipine is associated with the management of high blood pressure (hypertension).

One key study evaluated whether patient outcomes were affected; the research examined whether daily use of Lercanidipine was associated with a change in blood pressure readings. The study's authors reported that participants receiving Lercanidipine described a reduction in systolic and diastolic pressure compared to the control group.

A second study reported findings that Lercanidipine was associated with a change in the reported frequency of elevated pressure readings and changes in peripheral resistance were observed. The study involved a six-week observation period.

---

Safety and Tolerability Profile

The current body of evidence reports on the tolerability profile of Lercanidipine across study participants. The most frequently reported side effects were transient and included headache and flushing. Serious adverse events were reported infrequently in the reviewed clinical trials.

---

Combination Research

Research has explored whether using Lercanidipine in combination with other antihypertensive drugs is associated with different results. The trial focused on participants with severe or resistant hypertension. Findings were mixed; some participants reported achieving target blood pressure, while others did not experience a measurable difference.

---

Limitations and Exclusions

No studies directly comparing Lercanidipine with specific other calcium channel blockers were identified.

Clinical trials have not yet evaluated the use of this drug in people with certain severe cardiac conditions. The majority of studies excluded participants with pre-existing organ conditions. Data on continuous use of Lercanidipine is limited to studies lasting one year.

Key Studies & References NICE Guideline NG136: Hypertension in adults: diagnosis and management.

Common questions about Lerkamen 20 (FAQ)

Q: Are there any food restrictions I need to follow when taking Lerkamen 20?

A: Regulatory documents state that Lerkamen 20 is to be taken at least 15 minutes before any meal, which is a condition of use due to how food intake affects absorption. Additionally, the consumption of grapefruit or grapefruit juice is strictly prohibited due to a severe interaction.

Q: What happens if I forget to take my Lerkamen 20 dose?

A: The official product information specifies that if a dose is missed, the next step is to skip the forgotten dose and then take the next dose at the regularly scheduled time. It is important not to take a double dose to try and compensate for the missed one.

Q: Does Lerkamen 20 interact with common over-the-counter cold medicines?

A: Official information notes that Lerkamen 20 has potential interactions with many medicines, including those that affect the CYP3A4 enzyme in the body. Regulatory documents state that co-administration with other blood pressure-lowering agents is a consideration due to the potential for an additive hypotensive effect (causing blood pressure to drop too low).

Q: Can Lerkamen 20 affect my heart rate?

A: Yes, official safety information reports that Lerkamen 20 can affect heart rate. Fast heart rate (tachycardia) and palpitations are listed as Common side effects observed in clinical trials.

Q: Can Lerkamen 20 cause changes in mood or sleep?

A: Sleepiness, known medically as somnolence, is listed as a Rare side effect according to official product information. Changes in mood are not explicitly reported in the official lists of adverse reactions.

Q: Does Lerkamen 20 affect cholesterol levels?

A: Regulatory documents report that Lercanidipine, the active substance in Lerkamen 20, does not appear to influence adversely blood sugar or serum lipid (cholesterol) levels.

Q: Can Lerkamen 20 cause digestive issues like constipation or diarrhea?

A: Dyspepsia (indigestion), nausea, and upper abdominal pain are listed as uncommon side effects. Diarrhoea and vomiting are listed as Rare. Constipation is not explicitly mentioned in the official frequency-classified list of side effects.

Q: Is Lerkamen 20 a sustained-release or immediate-release tablet?

A: Lerkamen 20 is a film-coated tablet designed to be taken once daily. Its long duration of action is consistent with a long-acting formulation used for the maintenance of blood pressure control.

Q: What are the typical benefits of using Lerkamen 20?

A: The primary benefit and indication for Lerkamen 20 is the treatment of mild to moderate essential hypertension (high blood pressure) in adult patients.

Q: Does Lerkamen 20 help prevent heart attacks or strokes?

A: The official drug label only states the indication is to treat high blood pressure, which is a risk factor for cardiovascular events. The label does not make direct claims about preventing heart attacks or strokes, though isolated cases of myocardial infarction have been rarely observed with this drug class.

Q: How long will I likely need to take Lerkamen 20?

A: Treatment for essential high blood pressure is generally considered a long-term therapy. Official studies, however, report that data on the continuous use of Lercanidipine is limited to studies lasting one year.

Q: Can Lerkamen 20 be taken with diabetes medication?

A: Official documents do not list specific interactions with oral diabetes medications. As with all prescription drugs, co-administration with other medications is a regulatory consideration, especially regarding substances that could affect blood pressure or metabolism.

Q: What precautions should be taken when driving on Lerkamen 20?

A: The official label states Lerkamen 20 has no or negligible influence on the ability to drive. However, official safety information notes that caution is necessary because side effects like dizziness, fatigue, and rarely sleepiness (somnolence) may occur, which could potentially affect driving ability.

Q: Are there clinical trials comparing Lerkamen 20 to a placebo?

A: Yes, official product information confirms that Lercanidipine has been evaluated in double-blind, placebo-controlled clinical trials in patients with hypertension.

Q: Does Lerkamen 20 cause a persistent cough?

A: A persistent dry cough is a known side effect of some other classes of blood pressure medication, but it is not listed as a reported adverse reaction in the official safety profile for Lerkamen 20.

Q: Can Lerkamen 20 be used with diuretics (water pills)?

A: Yes, regulatory information indicates that Lercanidipine has been safely administered in combination with diuretics and other blood pressure-lowering agents.

Q: How quickly should I expect Lerkamen 20 to start working?

A: The full, intended therapeutic effect of Lerkamen 20 may take approximately two weeks to be fully realized after treatment begins or after a dose adjustment.

Q: Can Lerkamen 20 cause ankle swelling, and is that normal?

A: Yes, peripheral oedema (ankle swelling) is a Common side effect of Lerkamen 20, observed in 1 to 10 in 100 people according to clinical data.

Q: What common side effects are associated with Lerkamen 20?

A: Common side effects, reported in 1 to 10 out of every 100 people, include headache, peripheral oedema (swelling), tachycardia (fast heart rate), palpitations, and flushing (redness).

Q: Can Lerkamen 20 be taken with ibuprofen for pain relief?

A: Official product information does not list a specific interaction with ibuprofen. However, regulatory documents state that co-administration with other medications that might cause an additive hypotensive effect (a further reduction in blood pressure) is a safety consideration.

Q: Is it safe to drink alcohol while taking Lerkamen 20?

A: Official documents state that alcohol should be avoided because it may enhance the effect of Lerkamen 20, potentially causing blood pressure to drop too low.

Q: What should I do if I get a headache after starting Lerkamen 20?

A: Headache is a Common and often transient (temporary) side effect. Official guidance notes that all side effects should be reported to a healthcare professional, especially if they become persistent or bothersome.

Q: Does Lerkamen 20 make you tired or dizzy?

A: Dizziness and fatigue are listed as Uncommon side effects (1 to 10 in 1,000 people). Sleepiness (somnolence) is listed as Rare.

Q: Is it normal to feel flushed when taking Lerkamen 20?

A: Yes, flushing (a feeling of warmth or redness) is listed as a Common side effect. This means it is frequently observed in patients taking Lerkamen 20.

Q: Are there any known interactions between Lerkamen 20 and herbal supplements?

A: Official information does not specifically list herbal supplements but indicates that caution is necessary with any substance that can interfere with the CYP3A4 enzyme or cause an additive effect on blood pressure.

Q: Does Lerkamen 20 have a withdrawal effect if stopped suddenly?

A: Official guidance indicates that a healthcare professional must be consulted before stopping Lerkamen 20. Official information warns that stopping the treatment abruptly may cause a patient's blood pressure to increase again.

Q: What are the serious but rare side effects of Lerkamen 20?

A: Serious adverse reactions that have been reported as rare or very rare include angina pectoris (chest pain), syncope (fainting), and myocardial infarction (heart attack, very rare).

How to Store and Dispose of Lerkamen 20

The storage and disposal of Lerkamen 20 (Lercanidipine) must strictly adhere to the conditions mandated by official regulatory labeling to maintain product stability.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Do not store the medicinal product above 25°C.
Protection	Keep in the original package to shield the tablets from light and moisture.
Stability Note	If a tablet is divided, the remaining half must also be protected from light.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Lerkamen 20 must be disposed of in accordance with local requirements. It is prohibited to discard the medicine via wastewater or standard household waste; consult a pharmacist for guidance on how to properly throw away unused medicinal products.